Upstream Bio (UPB) Common Equity (2023 - 2025)
Historic Common Equity for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to $378.6 million.
- Upstream Bio's Common Equity rose 33615.6% to $378.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.6 million, marking a year-over-year increase of 33615.6%. This contributed to the annual value of $469.9 million for FY2024, which is 48160.26% up from last year.
- Latest data reveals that Upstream Bio reported Common Equity of $378.6 million as of Q3 2025, which was up 33615.6% from $408.7 million recorded in Q2 2025.
- Over the past 5 years, Upstream Bio's Common Equity peaked at $469.9 million during Q4 2024, and registered a low of -$160.3 million during Q3 2024.
- In the last 3 years, Upstream Bio's Common Equity had a median value of -$112.2 million in 2023 and averaged $114.1 million.
- The largest annual percentage gain for Upstream Bio's Common Equity in the last 5 years was 48160.26% (2024), contrasted with its biggest fall of 4287.46% (2024).
- Upstream Bio's Common Equity (Quarter) stood at -$123.1 million in 2023, then surged by 481.6% to $469.9 million in 2024, then decreased by 19.42% to $378.6 million in 2025.
- Its last three reported values are $378.6 million in Q3 2025, $408.7 million for Q2 2025, and $445.6 million during Q1 2025.